The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Article Page

Abstract

Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM) is considered as one of the commonly associated comorbid conditions in the HF population. The understanding of the molecular and metabolic models of HF has led to the utilization of therapeutic goals of T2DM in improving HFrelated complications. In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the T2DM population. This article will help the reviewer to comprehend the pathophysiology of HF and the potential role of SGLT-2 inhibitors in the management algorithm of HF and its associated risk factors in T2DM.

Keywords: SGLT-2 inhibitors, heart failure.

Citation: Saad M, Gomceli U, Ravi P, Lacoste AG, Shah N, Vittorio TJ. The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. Drugs in Context 2018; 7: 212549. DOI: 10.7573/dic.212549

Contributions: All authors contributed to the preparation of this article.

Disclosure and potential conflicts of interest: The authors declare that there is no conflict of interest in preparing this article. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2018/10/dic.212549-COI.pdf

Acknowledgments: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2018 Saad M, Gomceli U, Ravi P, Lacoste AG, Shah N, Vittorio TJ. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2018 Saad M, Gomceli U, Ravi P, Lacoste AG, Shah N, Vittorio TJ. https://doi.org/10.7573/dic.212549. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/the-role-of-sglt-2-inhibition-in-heart-failure

Correspondence: Timothy J Vittorio, Department of Cardiology, Bronxcare Health System/Bronxcare Hospital Center, 1650 Grand Concourse 12th Floor, Bronx NY, 10457, USA. tjvittorio@gmail.com

Provenance: invited; externally peer reviewed.

Submitted: 19 July 2018; Peer review comments to author: 28 August 2018; Revised manuscript received: 8 October 2018; Accepted: 9 October 2018; Publication date: 21 November 2018.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF